21.13
-0.18 (-0.84%)
| Penutupan Terdahulu | 21.31 |
| Buka | 21.22 |
| Jumlah Dagangan | 2,269,513 |
| Purata Dagangan (3B) | 4,138,043 |
| Modal Pasaran | 2,214,153,216 |
| Harga / Pendapatan (P/E Ke hadapan) | 16.98 |
| Harga / Jualan (P/S) | 0.970 |
| Harga / Buku (P/B) | 1.67 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Nov 2025 |
| Margin Keuntungan | -11.12% |
| Margin Operasi (TTM) | -40.33% |
| EPS Cair (TTM) | -2.64 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 80.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 248.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 118.73% |
| Nisbah Semasa (MRQ) | 4.02 |
| Aliran Tunai Operasi (OCF TTM) | -547.15 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -741.26 M |
| Pulangan Atas Aset (ROA TTM) | -2.19% |
| Pulangan Atas Ekuiti (ROE TTM) | -23.61% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Sarepta Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -1.25 |
|
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.42% |
| % Dimiliki oleh Institusi | 96.33% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 45.00 (Wells Fargo, 112.97%) | Beli |
| Median | 19.50 (-7.71%) | |
| Rendah | 5.00 (HC Wainwright & Co., -76.34%) | Jual |
| Purata | 22.50 (6.48%) | |
| Jumlah | 4 Beli, 3 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 19.76 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wedbush | 23 Jan 2026 | 34.00 (60.91%) | Beli | 21.13 |
| 09 Dec 2025 | 32.00 (51.44%) | Beli | 22.17 | |
| HC Wainwright & Co. | 14 Jan 2026 | 5.00 (-76.34%) | Jual | 22.80 |
| Barclays | 05 Nov 2025 | 20.00 (-5.35%) | Pegang | 18.67 |
| Guggenheim | 05 Nov 2025 | 19.00 (-10.08%) | Beli | 18.67 |
| Mizuho | 05 Nov 2025 | 26.00 (23.05%) | Beli | 18.67 |
| Wells Fargo | 05 Nov 2025 | 45.00 (112.97%) | Beli | 18.67 |
| Baird | 04 Nov 2025 | 15.00 (-29.01%) | Pegang | 16.20 |
| Piper Sandler | 30 Oct 2025 | 16.00 (-24.28%) | Pegang | 23.25 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |